A bottle-neck in recombinant antibody sandwich immunoassay development is pairing, demanding protein purification and modification to distinguish captor from tracer. We developed a simple pairing scheme using microliter amounts of E. coli osmotic shockates bearing site-specific biotinylated antibodies and demonstrated proof of principle with a single domain antibody (sdAb) that is both captor and tracer for polyvalent Marburgvirus nucleoprotein. The system could also host pairs of different sdAb specific for the 7 botulinum neurotoxin (BoNT) serotypes, enabling recognition of the cognate serotype. Inducible supE co-expression enabled sdAb populations to be propagated as either phage for more panning from repertoires or expressed as soluble sdAb for screening within a single host strain. When combined with streptavidin-g3p fusions, a novel transdisplay system was formulated to retrofit a semi-synthetic sdAb library which was mined for an anti-Ebolavirus sdAb which was immediately immunoassay ready, thereby speeding up the recombinant antibody discovery and utilization processes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495282 | PMC |
| http://dx.doi.org/10.1038/srep00807 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effects of Anti-Vascular Endothelial Growth Factor Loading Injections on Retinal Microvasculature in Diabetic Macular Edema.
Transl Vis Sci Technol
December 2024
Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Korea.
Purpose: To evaluate changes in the retinal microvasculature using widefield swept-source optical coherence tomography angiography (SS-OCTA) following three anti-vascular endothelial growth factor (anti-VEGF) loading injections for diabetic macular edema (DME).
Methods: Thirty-four treatment-naïve patients with DME received an initial three loading injections, followed by injections on an as-needed basis. Macular ischemia was evaluated based on the foveal avascular zone (FAZ) area, perfusion density, and vessel density on a 3 × 3-mm SS-OCTA image.
Single-cycle parainfluenza virus type 5 vectors for producing recombinant proteins, including a humanized anti-V5 tag antibody.
J Gen Virol
January 2025
Section for Pathogen Research, Institute for Infection and Immunity, St George's, University of London, London, SW17 0RE, UK.
Parainfluenza virus type 5 (PIV5) can cause either persistent or acute/lytic infections in a wide range of mammalian tissue culture cells. Here, we have generated PIV5 fusion (F)-expressing helper cell lines that support the replication of F-deleted viruses. As proof of the principle that F-deleted single-cycle infectious viruses can be used as safe and efficient expression vectors, we have cloned and expressed a humanized (Hu) version of the mouse anti-V5 tag antibody (clone SV5-Pk1).
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital, Mölndal, Sweden.
Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).
Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.
Adalimumab is a recombinant human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha). It has become an important drug in the treatment of inflammatory bowel diseases (IBD), which do not respond to initial medical treatment. The case of a patient with ulcerative proctitis is presented, who developed acute pleuropericarditis, after starting treatment with Adalimumab.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
Background: Alpha-internexin (AINX) is a type IV intermediate filament alongside the neurofilament triplet proteins. Although AINX is mostly expressed during the development of the brain, it is still present in mature neurons and reported to be involved in axonal outgrowth. Because of a lack of previously published studies quantifying AINX in cerebrospinal fluid (CSF), and its high sequence similarity with other neurofilaments, the objective of this project was to specifically detect AINX via antibody-based techniques and assess its biomarker capabilities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!